Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Psoriasis
•
Dermatology
Do you caution against starting biologics for psoriasis if patient has hepatitis A antibodies?
Answer from: at Academic Institution
No
Comments
at Jefferson Regional Medical Center
No
12435
Sign in or Register to read more
23143
Related Questions
Do you discontinue IL-17A, IL-17A/F, or IL-23 blockade in pregnant patients with psoriasis?
How would you manage active psoriasis and psoriatic arthritis in patient on Rituximab and prednisone for MPO positive vasculitis?
Do you wait on initiating biologic therapy for guttate psoriasis?
How do you approach management of patients with psoriatic arthritis who have significant improvement in skin disease, but ongoing inflammatory arthritis despite multiple DMARDs and/or biologics?
What are the best biologics for a pediatric patient with extensive guttate psoriasis that is poorly controlled on topicals?
How do you approach treatment change in patients with psoriasis who have been stable on an IL-17 or IL-23 agent but then begin to have breakthrough skin disease?
How do you approach managing nausea and GI side effects when initiating methotrexate?
How would you approach management of a patient with longstanding history of SLE, but having active psoriasis?
How do you counsel patients on the risks and benefits of an IL-23 agent versus an IL-17A or IL-17A/F agent?
Are you comfortable utilizing Stelara (ustekinumab) as biologic treatment of psoriasis for patients with a history of severe latex allergy?
No